10-K/A: Quantumzyme Amends 10-K, Reveals Deeper Losses and Going Concern Doubt

Quantumzyme Corp. filed an amendment to its annual report, disclosing increased net losses, a significant working capital deficit, and substantial doubt about its ability to continue as a going concern.

Summary

• Quantumzyme Corp. filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended July 31, 2025, primarily to include an updated audit report and reflect $54,500 in stock-based compensation for Mr. Naveen Krishnarao Kulkarni for fiscal year 2024.
• The company reported no revenues for the fiscal years ended July 31, 2025, and 2024.
• Net loss increased to $199,269 for the year ended July 31, 2025, from $178,569 in the prior year, driven by higher operating expenses and interest expense.
• Accumulated deficits reached $5,636,567 as of July 31, 2025.
• The company had a working capital deficit of $440,717 as of July 31, 2025, with total current assets of $584 and total current liabilities of $441,301.
• Cash used in operating activities increased to $125,181 in 2025 from $101,637 in 2024.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern due to net losses, accumulated deficits, and negative cash flows from operations.
• Quantumzyme is a biotransformation company focused on developing engineered enzymes for active pharmaceutical ingredient (API) production, with plans to expand into fragrance, flavors, and climate-impacting applications.
• The company's first product is an enzyme for Ibuprofen API production, targeting generic drug manufacturers, but it has not filed for patent protection due to cost considerations.
• The company relies on third-party manufacturers and distributors for commercialization and intends to generate revenue through technology transfer and royalties from licensing its enzymes.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the company's severe financial distress, including no revenue, increasing net losses, a significant working capital deficit, and explicit 'going concern' doubt. Operational risks are high due to a limited workforce, lack of formal agreements for key facilities, and unpatented core technology. While the business concept is positive, the current financial and operational state presents extreme challenges.

Positives

• The company has a clear vision to foster a clean, healthy, and well-protected environment by simplifying complex chemistry and reducing steps through quantum mechanics in biology.
• The company's biocatalysis solution offers advantages over traditional chemical processes, including reduced hazardous chemicals, lower pressure/temperature, minimal waste, lower costs, improved yield, reduced impurities, and ESG compliance benefits.
• The company has engineered its first product, an enzyme for Ibuprofen API production, a globally high-volume drug, aiming to make its manufacturing greener and more cost-effective.
• The company has established a Board of Directors with diverse experience, including two independent directors, and plans to set up a Scientific Advisory Board with accomplished scientists.

Negatives

• The company generated no revenues for the fiscal years ended July 31, 2025, and 2024, indicating it is still in the development stage.
• Net loss increased to $199,269 in 2025 from $178,569 in 2024, and accumulated deficits grew to $5,636,567, raising significant financial concerns.
• A substantial working capital deficit of $440,717 as of July 31, 2025, highlights severe liquidity issues.
• Cash used in operating activities increased, further stressing the company's financial position.
• The company has only one employee, Mr. Kulkarni, which limits its capacity to manage product development, regulatory compliance, and business development effectively.
• Material weaknesses in internal control over financial reporting exist due to a lack of segregation of duties and limited resources, with no immediate plan to hire additional personnel due to financial constraints.
• The company has not filed for patent protection for its initial product, citing that costs outweigh anticipated benefits, which could expose its intellectual property.

Risks

• The company is a high-risk investment and speculative in nature, with the potential for complete loss of investment.
• Financial projections are based on assumptions and may not prove accurate, cautioning against excessive reliance.
• Failure to establish and maintain strategic partnerships on commercially reasonable terms could materially and adversely affect the business.
• The loss of Mr. Kulkarni, the sole key member of the management team, could disrupt operations and adversely affect business growth.
• Inability to hire qualified personnel and retain or motivate key personnel may hinder effective growth.
• A limited workforce of one employee may hinder the ability to execute business objectives and increases exposure to risks associated with workload constraints and potential turnover.
• A decline in general economic conditions could have a material adverse effect on business, financial condition, and results of operations.
• The sole officer and director have limited experience managing a public company, which may impede successful operation as a public entity.
• The company may need substantial additional capital in the future, and if future financings involve equity, existing stockholders will suffer dilution; debt financing may impose restrictive covenants.
• Termination or expiration of patent protection for customers' active pharmaceutical ingredients (API) could materially and adversely affect revenues.
• Dependence on a limited number of contract manufacturers for large-scale enzyme production poses risks of difficulties, interruptions, and manufacturing delays.
• The lack of formal agreements for off-site testing facilities may disrupt operations, increase costs, and cause delays in product development.
• Competitors with greater resources and experience may develop superior products or technologies, making the company's offerings obsolete or gaining market share.
• Ethical, legal, and social concerns about genetically engineered products and processes could limit or prevent the use and acceptance of the company's technology.
• Efforts to prosecute, maintain, protect, and/or defend intellectual property rights may not be successful, especially given the decision not to patent the initial product.
• Third parties may claim infringement, violation, or misappropriation of their intellectual property rights, leading to costly litigation.
• The company's financial status creates substantial doubt about its ability to continue as a going concern, with insufficient cash and no significant revenue source.
• Inability to enforce intellectual property rights throughout the world, particularly in countries with less robust protection.
• Confidentiality and non-use agreements may not adequately prevent disclosures and non-use of trade secrets and other proprietary information.
• Quarterly financial results are expected to fluctuate significantly due to various factors.
• A dual-class capital structure limits the ability of other shareholders to influence corporate decisions and may discourage beneficial merger or acquisition attempts.
• The company's shares are classified as 'Penny Stock,' which impairs trading liquidity and may reduce trading activity.
• As an Emerging Growth Company, the decision to comply with reduced disclosure requirements could make shares less attractive to investors and make it difficult to raise capital.

Future Outlook

The company intends to expand beyond the API marketplace into fragrance and flavors, climate-impacting applications like sustainable materials, plastic degradation, and carbon capture. It aims to establish itself as an industry leader by solving complex chemistry problems. The company anticipates generating revenues from future technology, products, and services, but acknowledges that its future operations are dependent on successful execution of its business plan and obtaining additional financing. Management expects operating expenses to increase in future years due to increased operating activity.

Management Comments

• "We intend to expand beyond the API marketplace and engineer enzymes for the use and deployment in other business sectors such as fragrance and flavors, climate impacting applications like sustainable materials, plastic degradation and carbon capture."
• "Our goal is to help to foster a clean, healthy, and well protected environment supporting a sustainable society and economy."
• "Ultimately, we want to fulfil our vision by developing a focused approach to aid all chemical companies to harness the power of technology by simplifying complex chemistry and reducing the number of steps by implementing scientific rationale like quantum mechanics in biology."
• "As we continue to develop and implement our plan of operation, we intend to establish ourselves as industry leaders by solving complex chemistry problems in the pharmaceutical, fragrances, and flavors sectors."
• "Our goal is to bring back manufacturing capabilities in the USA by making the manufacturing of Ibuprofen greener, cost effective and more environmentally friendly."
• "Management believes that it is essential for any company involved in bioengineering activities, including enzyme production, to consult with relevant government agencies and legal experts to ensure compliance with applicable regulations and standards in both the U.S.A. and the U.A.E."
• "We intend to stay informed about updates and changes to regulations that may affect our current and future operations."
• "We believe that our methods, approach, and plan of operation will allow us to offer similar services at competitive pricing."
• "We believe our success will be in our dedication to our business and scientific principals which will be our key differentiator as we ramp up operations."
• "Management and the Board of Directors intend to adopt and implement a Code of Ethics consistent with the requirements of Item 406 of Regulation S-K during the fiscal year ending July 31, 2026."
• "The Board intends to appoint at least one director who qualifies as an audit committee financial expert as the Company’s financial position and staffing permit."
• "In order to address and resolve the weaknesses [in internal control], the Company will endeavor to locate and appoint additional qualified personnel to the board of directors and pertinent officer positions as the Company’s financial means allow."

Industry Context

Quantumzyme operates in the dynamic and evolving enzyme engineering field within the broader biotechnology sector. This industry focuses on modifying and optimizing enzymes for various industrial, medical, and environmental applications, driven by advances in genetic engineering, protein design, and computational biology. Key growth factors include demand for sustainable solutions and enzyme versatility. The company aims to leverage its 'clean and green chemistry' approach to differentiate itself in a market with established players like Novozymes, DuPont Industrial Biosciences, BASF, and Codexis, who possess significantly greater resources. Quantumzyme's focus on biotransformation for API production, particularly Ibuprofen, aligns with the industry's shift towards sustainable practices and reducing environmental impact.

Comparison to Industry Standards

• Quantumzyme is an early-stage company with no revenue, which is significantly below the performance of established industry leaders like Novozymes (a global leader in bio-innovation with substantial revenue and market presence), DuPont Industrial Biosciences, and BASF.
• Unlike many established players who invest heavily in intellectual property, Quantumzyme has not filed for patent protection for its initial product, citing cost, which is a deviation from standard competitive practices in the biotechnology sector where IP is crucial for market advantage.
• The company's reliance on a single employee and lack of formal agreements for testing facilities contrasts sharply with the robust operational structures and R&D capabilities of larger competitors such as Codexis, which specializes in enzyme engineering for pharmaceuticals and biofuels with significant R&D investment.
• The company's financial position, marked by substantial net losses and a going concern doubt, is far from the financial stability and profitability typically seen in mature biotechnology companies or even well-funded emerging growth companies in the enzyme engineering space.

Management Changes

Corporate Governance

Legal Proceedings

• The company may, from time to time, be involved in various legal proceedings incidental to the conduct of its business.
• Management is currently not aware of any material pending or threatened legal proceedings or claims that could have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• On February 21, 2023, the company acquired enzyme-engineering technology assets from Quantumzyme Inc. and Mr. Naveen Krishna Rao Kulkarni (sole officer, director, and shareholder of Quantumzyme Inc.) in exchange for 1,500,000 restricted shares of the company's common stock issued to Mr. Kulkarni, representing approximately 73% of outstanding shares.
• As of July 31, 2025, and 2024, the amount due to related parties was $17,002 and $15,852, respectively. These amounts are non-interest bearing and due on demand.
• Mr. Kulkarni's Executive Employment Agreement, effective June 1, 2023, includes a base salary of $90,000 per year (accruing), 29,500,000 restricted common shares, and 500,000 restricted Series B Preferred Stock shares.
• Mr. Kulkarni received $54,000 in stock compensation for fiscal year 2024.
• The company does not have formal written policies or procedures for related party transactions, but the Board of Directors reviews and approves all such transactions.

Stakeholder Impact

• **Shareholders:** Face significant risk of complete loss of investment due to the company's 'going concern' doubt, increasing losses, and need for substantial future capital which could lead to dilution. The dual-class capital structure limits common shareholders' influence.
• **Employees:** Currently, only one employee (Mr. Kulkarni) is noted, indicating high workload and dependence on a single individual. Future hiring is contingent on financial means.
• **Customers (potential):** The company's reliance on third-party manufacturers and lack of patent protection for its initial product could introduce supply chain and intellectual property risks for potential licensees.
• **Creditors:** Face elevated risk due to the company's substantial accumulated deficit, negative cash flows, and 'going concern' doubt, which may impair the company's ability to repay debts.
• **Regulatory Authorities:** The company's material weaknesses in internal control and lack of an audit committee financial expert may draw increased scrutiny, although it is an Emerging Growth Company with reduced reporting requirements.

Next Steps

• Identify 3rd party manufacturers and distributors capable of large-scale enzyme manufacturing and product distribution.
• Understand market needs, demand-supply relationships, technical feasibility, and commercial viability for the Ibuprofen enzyme.
• Engage in discussions with potential end-users regarding the impact and benefits of the proposed solution.
• Work with third-party manufacturing partners to ensure compliance with all relevant regulatory requirements before commercialization.
• Continually focus on and implement learnings in understanding enzymes, genetic & protein engineering, directed evolution, structural biology, computational biology, immobilization techniques, high-throughput screening, and synthetic biology.
• Interact with experts in the field through conferences and symposia, and build academic collaborations to identify novel approaches.
• Seek larger office space as the plan of operation advances and business grows.
• Endeavor to locate and appoint additional qualified personnel to the board of directors and pertinent officer positions as financial means allow, to address material weaknesses in internal control.
• Management and the Board of Directors intend to adopt and implement a Code of Ethics during the fiscal year ending July 31, 2026.
• The Board intends to appoint at least one director who qualifies as an audit committee financial expert as the company's financial position and staffing permit.

Key Dates

Recommendation

The company presents an extremely high-risk investment profile. It has no revenue, consistently increasing net losses, a substantial accumulated deficit, and a severe working capital deficit. The auditor has raised 'substantial doubt' about its ability to continue as a going concern. Operational risks are significant due to a single employee, reliance on informal third-party agreements, and a decision not to patent its initial product. While the underlying technology concept is promising, the current financial instability, governance weaknesses, and the explicit need for substantial future capital (with no firm agreements) make the stock highly speculative with a high probability of complete loss for investors. A seasoned investor would view this as an unsustainable business model in its current state.

Keywords

Enzyme Engineering, Biotransformation, Active Pharmaceutical Ingredients (API), Green Chemistry, Sustainable Manufacturing, Ibuprofen Production, Biocatalysis, SEC Filing, 10-K/A, Going Concern, Early Stage Company, Intellectual Property, Corporate Governance, Financial Reporting